# Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

> **NCT02676596** · PHASE1 · COMPLETED · sponsor: **Kowa Research Institute, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** K-312 10 mg QD
- **DRUG:** K-312 25 mg QD
- **DRUG:** K-312 50 mg QD
- **DRUG:** K-312 100 mg QD
- **DRUG:** K-312 200 mg QD
- **DRUG:** K-312 400 mg QD
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02676596
- **Lead sponsor:** Kowa Research Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-11
- **Final completion:** 2015-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02676596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02676596, "Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02676596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*